Diaceutics (LON:DXRX) Releases Earnings Results

Diaceutics (LON:DXRX) posted its earnings results on Tuesday. The company reported GBX (3.27) EPS for the quarter, Digital Look Earnings reports. Diaceutics had a net margin of 0.25% and a return on equity of 0.25%.

Diaceutics Stock Down 0.1%

LON:DXRX traded down GBX 0.14 during midday trading on Wednesday, reaching GBX 185.86. The company had a trading volume of 1,030,922 shares, compared to its average volume of 206,906. The stock’s fifty day simple moving average is GBX 146.97 and its 200-day simple moving average is GBX 151.24. The company has a current ratio of 3.43, a quick ratio of 9.92 and a debt-to-equity ratio of 2.85. The firm has a market capitalization of £157.72 million, a price-to-earnings ratio of 1,689.61 and a beta of 0.88. Diaceutics has a 12-month low of GBX 125 and a 12-month high of GBX 191.

Analyst Ratings Changes

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Diaceutics presently has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.